20 years and $2B later, FDA approves gene-silencing drug

01/31/2013 | New York Times (tiered subscription model), The · Xconomy

The FDA approved antisense drug Kynamro to treat homozygous familial hypercholesterolemia, a rare, inherited disorder. The technology on which the drug is based was initially developed by Gilead Sciences, which sold its patents to Isis Pharmaceuticals. Sarepta Therapeutics and Prosensa are developing gene-silencing drugs to treat muscular dystrophy.

View Full Article in:

New York Times (tiered subscription model), The · Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI